1. Kazia Therapeutics

2. Forward-Looking Statements

3. Investment Highlights

4. Kazia strategy to develop high-quality assets from external sources

5. A strong team brings international experience in big pharma and early-stage biotech

6. Two clinical programs, with value-driving inflection points providing impactful news-flow during 2018-19

7. Kazia is NASDAQ & ASX listed with ~$9.3M of current assets at 30 June 2018

8. Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer

9. Current standard of care is essentially ineffective in approximately 65% of GBM cases

10. The PI3K inhibitor class is well-validated, but GDC-0084 is the only brain-penetrant drug in GBM

11. Phase I of GDC-0084 established dosing and showed favourable safety

12. In GDC-0084 phase I, 7 / 27 patients (26%) showed a ‘metabolic partial response’ on FDG-PET

13. Multipart GDC-0084 phase II design allows for frequent data read-outs to inform partnering and early approval

14. Recent collaboration with St Jude, a leading US paediatric hospital, expands GDC-0084 into childhood brain cancer

15. Investment Highlights

16. Kazia Therapeutics